News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
637,113 Results
Type
Article (20212)
Company Profile (201)
Press Release (616288)
Multimedia
Podcasts (55)
Webinars (13)
Section
Business (211400)
Career Advice (707)
Deals (31885)
Drug Delivery (50)
Drug Development (64212)
Employer Resources (57)
FDA (13382)
Job Trends (11688)
News (299657)
Policy (23108)
Tag
2027 BioCapital Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (1519)
Accelerated approval (32)
ADA (26)
Adcomms (2)
Allergies (161)
Alliances (47187)
ALS (150)
Alzheimer's disease (1299)
Antibody-drug conjugate (ADC) (416)
Approvals (14118)
Artificial intelligence (719)
ASCO (204)
Autoimmune disease (279)
Automation (61)
Bankruptcy (298)
Best Places to Work (9349)
BIO (51)
Biologics (2)
BIOSECURE Act (7)
Biosimilars (138)
BioSpace Insights (96)
Biotechnology (137)
Bladder cancer (170)
Brain cancer (52)
Breast cancer (634)
Cancer (4967)
Cardiovascular disease (328)
Career advice (638)
Career pathing (13)
CAR-T (313)
CDC (12)
Celiac Disease (1)
Cell therapy (817)
Cervical cancer (46)
Clinical research (57100)
Collaboration (2080)
Commercialization (4)
Company closure (1)
Compensation (1521)
Complete response letters (41)
COVID-19 (1507)
CRISPR (118)
C-suite (1116)
Cystic fibrosis (114)
Data (7220)
Decentralized trials (2)
Denatured (28)
Depression (123)
Dermatology (77)
Diabetes (458)
Diagnostics (6580)
Digital health (67)
Diversity (7)
Diversity, equity & inclusion (13)
Drug discovery (318)
Drug pricing (24)
Drug shortages (7)
Duchenne muscular dystrophy (201)
Earnings (84701)
Editorial (11)
Employer branding (9)
Employer resources (54)
Events (108530)
Executive appointments (1018)
FDA (16993)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (19)
Frontotemporal dementia (30)
Funding (1578)
Gene editing (244)
Generative AI (54)
Gene therapy (584)
GLP-1 (502)
Government (1844)
Grass and pollen (4)
Guidances (356)
Healthcare (14456)
Hematology (123)
HIV (71)
Huntington's disease (28)
IgA nephropathy (78)
Immunology and inflammation (140)
Immuno-oncology (72)
Indications (196)
Infectious disease (1791)
Inflammatory bowel disease (161)
Inflation Reduction Act (6)
Influenza (126)
Intellectual property (315)
Interviews (87)
IPO (14986)
IRA (10)
Job creations (2764)
Job search strategy (573)
JPM (22)
Kidney cancer (19)
Labor market (27)
Layoffs (177)
Leadership (8)
Legal (6046)
Licensing (9)
Liver cancer (72)
Longevity (30)
Lung cancer (617)
Lymphoma (348)
Machine learning (56)
Management (20)
Manufacturing (977)
Marketing (10)
MASH (141)
Medical device (13705)
Medtech (13941)
Mergers & acquisitions (18236)
Metabolic disorders (941)
mRNA (197)
Multiple sclerosis (137)
NASH (7)
Neurodegenerative disease (336)
Neuropsychiatric disorders (54)
Neuroscience (2486)
NextGen: Class of 2026 (5063)
Non-profit (2035)
Now hiring (20)
Obesity (306)
Opinion (119)
Ovarian cancer (192)
Pain (215)
Pancreatic cancer (279)
Parkinson's disease (302)
Partnered (26)
Patents (605)
Patient recruitment (700)
Peanut (61)
People (53257)
Pharmaceutical (41)
Pharmacy benefit managers (12)
Phase 1 (18983)
Phase 2 (25442)
Phase 3 (17203)
Pipeline (9503)
Policy (80)
Postmarket research (1731)
Preclinical (8189)
Press Release (69)
Prostate cancer (271)
Psychedelics (10)
Radiopharmaceuticals (319)
Rare diseases (779)
Real estate (4887)
Recruiting (25)
Regulatory (19582)
Reports (28)
Research institute (1589)
Resumes & cover letters (111)
Rett syndrome (47)
RNA editing (19)
RSV (66)
Schizophrenia (118)
Series A (282)
Series B (198)
Service/supplier (6)
Sickle cell disease (77)
Special edition (1)
Spinal muscular atrophy (106)
Sponsored (26)
Startups (3312)
State (2)
Stomach cancer (4)
Supply chain (80)
Tariffs (12)
The Weekly (25)
Vaccines (712)
Venture capital (68)
Weight loss (114)
Women's health (107)
Worklife (4)
Date
Today (12)
Last 7 days (302)
Last 30 days (1962)
Last 365 days (25082)
2026 (16405)
2025 (25199)
2024 (30104)
2023 (34735)
2022 (45176)
2021 (48663)
2020 (45649)
2019 (36326)
2018 (27302)
2017 (27221)
2016 (26259)
2015 (32732)
2014 (27755)
2013 (23753)
2012 (25695)
2011 (26031)
2010 (24896)
Location
Africa (457)
Alabama (88)
Alaska (6)
Arizona (364)
Arkansas (16)
Asia (33595)
Australia (5248)
California (13639)
Canada (3725)
China (1112)
Colorado (599)
Connecticut (536)
Delaware (302)
Europe (64086)
Florida (2062)
Georgia (443)
Hawaii (4)
Idaho (60)
Illinois (1031)
India (88)
Indiana (442)
Iowa (22)
Japan (581)
Kansas (127)
Kentucky (46)
Louisiana (42)
Maine (39)
Maryland (1520)
Massachusetts (9547)
Michigan (400)
Minnesota (752)
Mississippi (6)
Missouri (149)
Montana (31)
Nebraska (19)
Nevada (131)
New Hampshire (89)
New Jersey (3187)
New Mexico (27)
New York (3457)
North Carolina (1664)
North Dakota (10)
Northern California (6786)
Ohio (387)
Oklahoma (23)
Oregon (30)
Pennsylvania (2617)
Puerto Rico (26)
Rhode Island (50)
South America (733)
South Carolina (90)
South Dakota (1)
Southern California (5604)
Tennessee (199)
Texas (2250)
United States (46774)
Utah (425)
Vermont (2)
Virginia (239)
Washington D.C. (52)
Washington State (1101)
West Virginia (3)
Wisconsin (150)
Wyoming (2)
637,113 Results for "cerveau technologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
Cerveau Technologies, Inc. announced a license agreement with LEXEO Therapeutics, Inc., which will enable LEXEO to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.
November 7, 2022
·
1 min read
Business
Cerveau Technologies Inc. and Prothena Sign Agreement to Provide Novel Tau Imaging Biomarker for Research and Development of Investigational Therapeutics for Neurodegenerative Diseases
Cerveau Technologies, Inc. today announced a research collaboration agreement with Othair Prothena Limited, a subsidiary of Prothena Corporation plc (Prothena), which will enable Prothena to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.
January 10, 2023
·
1 min read
Genetown
Cerveau Technologies Inc. and Alnylam® Pharmaceuticals Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
Cerveau Technologies, Inc. announced a research collaboration agreement with Alnylam® Pharmaceuticals, which will enable Alnylam to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.
September 1, 2022
·
1 min read
Press Releases
FOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.
July 29, 2026
·
6 min read
Business
Cerveau Technologies Inc. Signs Agreement with Roche to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
Cerveau Technologies, Inc. announced a research collaboration agreement with Roche Products Limited, on the use of Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.
March 10, 2022
·
1 min read
Press Releases
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
July 22, 2026
·
8 min read
Press Releases
BioStem Technologies Announces Nasdaq Uplisting
August 7, 2026
·
5 min read
Business
Cerveau Technologies, Inc. and Nihon Med-Physics Co., Ltd. Announce Manufacturing Service Agreement for [18F]MK-6240 in Japan
Cerveau Technologies, Inc. (Cerveau) and Nihon Medi-Physics (NMP), a leading company for radiopharmaceuticals in Japan, today announced that they signed a manufacturing service agreement, in which Cerveau grants NMP the right to manufacture [18F]MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent.
February 22, 2022
·
2 min read
Press Releases
IonQ Completes Acquisition of SkyWater Technology
August 2, 2026
·
6 min read
Press Releases
BioStem Technologies Reports Second Quarter 2026 Financial Results
August 13, 2026
·
12 min read
1 of 63,712
Next
